Are you hunting some big dividend yields to combat falling interest rates? If you are, then you may want to check out the ASX dividend shares listed below.
Analysts have named them as buys and are forecasting yields of 5%+ in the near term. Here's what you need to know about them:
Image source: Getty Images
GDI Property Group Ltd (ASX: GDI)
GDI Property could be an ASX dividend share to buy. It is a property owner and fund manager with investments across Sydney, Brisbane, Perth, South East Queensland, and North Queensland.
The team at Bell Potter is positive on GDI Property and sees a lot of value in its shares at current levels. The broker recently put a buy rating and 80 cents price target on them.
Its analysts also expect some big dividend yields in the near term. Its analysts are forecasting dividends per share of 5 cents in both FY 2025 and FY 2026. Based on the current GDI Property share price of 67 cents, this equates to dividend yields of 7.4% for both years.
Healthco Healthcare and Wellness REIT (ASX: HCW)
HealthCo Healthcare & Wellness REIT could also be an ASX dividend share to buy now according to Bell Potter.
This real estate investment trust is focused on investing in hospitals, aged care, childcare, government, life sciences and research, and primary care and wellness property assets.
Bell Potter likes the HealthCo Healthcare & Wellness REIT due to its "significant scope for growth with an estimated $218 billion addressable market." The broker has a buy rating and $1.50 price target on its shares.
In respect to dividends, the broker is expecting the company to pay dividends of 8.4 cents per share for FY 2025 and then 8.7 cents per share in FY 2026. Based on the current Healthco Healthcare and Wellness REIT unit price of $1.18, this will mean dividend yields of 7.1% and 7.4%, respectively.
IPH Ltd (ASX: IPH)
Finally, Goldman Sachs thinks that IPH could be an ASX dividend share to buy.
It is a leading intellectual property solutions company offering a wide range of services and products to a diverse client base. This includes some of the world leading companies, multi-nationals, universities, public sector research organisations, foreign associates and other corporate and individual clients.
Goldman likes IPH due to its defensive earnings and organic growth potential. It has a buy rating and $8.25 price target on its shares.
As for income, it is expecting fully franked dividends per share of 37 cents in FY 2025 and then 40 cents in FY 2026. Based on the current IPH share price of $5.70, this represents yields of 6.5% and 7%, respectively.
